Streptococcus agalactiae, or Lancefield's group B Streptococcus (GBS), is a major cause of sepsis, meningitis, and pneumonia in the newborn infant (2). Early-onset disease (manifested within the first 7 days of age) has an incidence of 1.3 to 3.0 per 1,000 live births and is associated with a mortality rate of 20%, whereas late-onset infection (developing at >7 days of age) has an incidence of 1.0 to 1.7 per 1,000 live births and is associated with a mortality rate of 10% (2). Four of the seven GBS serotypes identified thus far (Ta, Tb, TI, and III) 
Streptococcus agalactiae, or Lancefield's group B Streptococcus (GBS), is a major cause of sepsis, meningitis, and pneumonia in the newborn infant (2) . Early-onset disease (manifested within the first 7 days of age) has an incidence of 1.3 to 3.0 per 1,000 live births and is associated with a mortality rate of 20%, whereas late-onset infection (developing at >7 days of age) has an incidence of 1.0 to 1.7 per 1,000 live births and is associated with a mortality rate of 10% (2) . Four of the seven GBS serotypes identified thus far (Ta, Tb, TI, and III) are responsible for the majority of reported cases of infection in both neonates and adults in the United States (2, 12) . In addition to these four recognized major serotypes, recent reports of invasive infections caused by type V GBS suggest that this newly characterized serotype also may account for a significant fraction of neonatal infections now or in the future (15, 17, 28) .
Immunologic strategies proposed for the prevention of GBS disease include treatment of newborns with intravenous immunoglobulin preparations (13, 31) and active immunization of women with a vaccine against GBS (4, 6) . The goal of both approaches is to supply the newborn with protective levels of immunoglobulin G (IgG) specific for the GBS capsular polysaccharide antigen, because antibodies to this cell surface t National Research Council of Canada paper 37390. component are protective (1, 3, 4, 7, 9, 11) . Capsular polysaccharides of types Ta, II, and III have been tested as experimental vaccines in volunteers (5) . The rate of immune response among adults with low preexisting antibody levels who were given purified GBS capsular polysaccharide ranged from 40% for type Ta to 88% for type IT (5) . To enhance their immunogenicity, type Ta, II, and III GBS polysaccharides have been coupled to immunogenic protein carriers to form polysaccharide-protein conjugate vaccines (20, 25, 26, 32, 33) . Despite differences in coupling strategy and in the choice of protein carrier, all GBS glycoconjugate vaccines exhibited greater immunogenicity in laboratory animals than did uncoupled GBS polysaccharides. Lagergard et al. (20) coupled cyanogen bromide-activated GBS type III capsular polysaccharide to tetanus toxoid (TI) by carbodiimide reduction, with adipic acid dihydrazide as a spacer. When administered to mice, this conjugate vaccine elicited type TI1-specific IgG that opsonized GBS type III organisms (20) . A coupling method similar to that used by Lagergard et al. (20) was used in the generation of a trivalent (types Ta, IT, and III) GBS glycoconjugate vaccine, with detoxified Pseudomonas aeruginosa toxin A as the carrier protein (26) . In rabbits, this trivalent vaccine elicited antibodies that were opsonically active in vitro against type Ta, IT, and III GBS (26) .
In contrast to the glycoconjugates described above, all saccharide-protein conjugates synthesized and tested in our laboratory have utilized reductive amination as the coupling method. We have reported the synthesis and immunogenicity testing of oligosaccharide-protein conjugate vaccines based on the GBS type III polysaccharide (23, 24) and of type Ta, IT, and III polysaccharide-protein conjugates (25, 32, 33 (kindly provided by Amvax Inc., Beltsville, Md.) was purified to its monomer form by gel filtration chromatography on a Sephacryl S-300 HR column (2.6 by 91.5 cm; Pharmacia LKB, Uppsala, Sweden). After addition of sodium cyanoborohydride (41 mg), the type lb polysaccharide-TT mixture was incubated at 37°C for 37 days. The progress of the conjugation was monitored by analysis of aliquots, with use of a Superose 6 gel filtration column and a fast protein liquid chromatography system (Pharmacia LKB), as described previously (32) . GBS lb-TI' vaccine was purified by gel filtration chromatography on the Sephacryl S-300 HR column. Fractions corresponding to the void-volume peak from this column were pooled, unreacted aldehydes were reduced by the addition of sodium borohydride, and the mixture was dialyzed against a total of 32 liters of sterile water at 4°C. The purified GBS lb-TT vaccine was analyzed for carbohydrate content by the phenol-sulfuric acid assay (10) combined with alum, in a total volume of 0.25 ml of PBS. All mice were bred after administration of the primary dose. Booster doses of vaccine, also mixed with alum, were administered by the same route 2 weeks after the primary dose. The first litters of pups were born to these dams 26 to 39 days and the second litters were born 54 to 66 days after primary vaccination. Within 36 h of birth, pups were challenged intraperitoneally with 0.05 ml of GBS. The GBS inoculum was prepared as follows: frozen stock cultures of GBS were thawed and streaked for isolation on a blood agar plate, and the plate was incubated overnight at 37°C. The following day, the culture was assessed for purity and was used to seed 5-ml tubes containing Todd-Hewitt broth. Cells incubated at 37°C with end-over-end mixing were grown to an A650 of 0.3. Serial 10-fold dilutions were made in Todd-Hewitt broth, and the appropriate dilution was used as the challenge inoculum. Cells were enumerated by the standard plate count method. Newborn pups remained with their own dam for the duration of the 48-h observation period after challenge. Survival of pups was assessed 48 h after challenge. IbOX+TT failed to elicit type-specific IgG (Table 3 ).
In vitro functional activity of Lb-TT vaccine-induced rabbit antisera. We previously showed that antibodies elicited in rabbits by la-TT, II-TT, and III-TT vaccines opsonized GBS of the homologous serotype for phagocytic killing by human blood leukocytes (25, 32, 33) . In the present study, serum (diluted 1:100) from each of the three rabbits immunized with lb-TT vaccine, in combination with complement and human blood leukocytes, reduced counts of GBS type lb strain H36B by >2 log1o CFU after 60 min of incubation (Table 4 ). In contrast, neither pooled preimmunization serum from rabbits that were later immunized with the Tb-TT vaccine nor serum from the rabbit immunized with IbOX+TT opsonized GBS type Tb cells for killing by leukocytes (Table 4) .
Protective efficacy of GBS tetravalent vaccines in mice. Transplacentally acquired immunity to four GBS serotypes in mice born to dams vaccinated with GBS tetravalent conjugate vaccine (la-IT, Tb-IT, 11-TT, and III-TT), GBS tetravalent polysaccharide vaccine (Ia, Tb, LT, and TTL), or uncoupled TT was evaluated. These vaccines were administered to dams in alum rather than in CFA because the former is acceptable for human use. Protection of neonatal pups against challenge with GBS (within 36 h of birth) was evaluated in two successive sets of litters. In the first set of litters born to dams given GBS tetravalent conjugate vaccine, all pups challenged were protected against type Ta strain 515, type lb strain H36B, and type III strain M781 (Table 5 ). The survival rates in these groups were statistically higher than those in litters born to dams that received either uncoupled IT or GBS tetravalent polysaccharide vaccine (Table 5) . However, the rates of survival of pups in the three vaccine groups challenged with GBS type IT strain 18RS21 did not differ statistically (Table 5) .
Without further vaccination, the same female mice were rebred, and the second set of litters was challenged with GBS. As in the first set of litters, there was 100% protection against challenge with GBS types Ta and III (Table 6 ). The survival rate was 76% among pups challenged with type lb and 97% among those challenged with type LL (Table 6 ). The level of protection afforded to all groups of second-litter pups born to dams that received the GBS tetravalent conjugate vaccine was significantly higher (P < 0.0001) than that conferred on pups born to dams that received either the GBS tetravalent polysaccharide vaccine or uncoupled IT (Table 6) .
Opsonophagocytosis of GBS vaccine-induced mouse anti- (Fig. 2) . In contrast, in each of the three successive litters born to dams vaccinated with type III capsular polysaccharide, fewer than 30% of pups survived challenge with an ordinarily lethal dose of GBS (Fig. 2) .
DISCUSSION
Susceptibility to GBS infection in the neonate is correlated with the presence of low levels, or the absence, of capsular polysaccharide-specific antibody in the mother (4) . This observation, together with experimental evidence for a protective role of polysaccharide-specific antibodies, provides the rationale for development of a maternal GBS vaccine based on the type-specific GBS polysaccharides. Like those to other bacterial polysaccharides, the human antibody response to purified GBS capsular polysaccharides is variable and depends on the immune status of the individual (5, 6 (20, 25, 26, 32, 33) .
The current studies were designed to formulate a multivalent GBS vaccine and test it in an animal model. A maternal vaccination model in mice was utilized to simulate the intended use of such a vaccine in humans. The model has several features that make it attractive for testing the potential efficacy of a maternal vaccine. Demonstration of efficacy in this model requires that the vaccine elicit specific maternal antibodies, that vaccine-stimulated IgG antibodies cross the placenta, and that the antibodies function in the neonatal animal to mediate opsonophagocytic killing of GBS, thereby providing protection against an ordinarily lethal GBS challenge.
In our studies, immunity conferred by breast milk was not excluded. However, others have shown that while naive rat pups were only partially protected by breast milk from dams immunized with a GBS whole-cell vaccine, pups born to immunized dams were completely protected, even when nursed by nonimmune dams (16) . These data suggest that transplacental transfer is likely to be the major mechanism of acquisition of maternal antibodies.
Because has not been defined.
Should epidemiologic surveillance indicate that GBS type V or other serotypes are becoming more prevalent in neonatal infections, the structural similarity of all GBS capsular polysaccharides will permit the addition of one or more additional or alternative GBS polysaccharide-TT conjugates to the multivalent formulation. Our findings suggest that a multivalent GBS conjugate vaccine of the design described in this report might be an effective maternal vaccine to protect human infants against neonatal GBS infection.
